Per Reuters, Astrazeneca CEO Pascal Soriot announced that the company is on track to deliver at least 15 new medicines this decade and expect to start at least 30 new late-stage clinical trials in 2023.
AstraZeneca also predicts a return to growth in China, one of its key markets, after reporting a second consecutive quarter of growth, despite ongoing drug price pressure.
The CEO stated that they are "very much on track to deliver [their] industry-leading growth ambitions for 2025, but also beyond until 2030." Despite facing higher costs due to the ongoing pandemic and the war in Ukraine, AstraZeneca's operating profit margins have risen from 27% in 2021 to 30% in 2022 and are expected to continue to improve steadily.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.